A completed phase II study in 2008 (n = 50) confirmed its α-tumor activity in PDGF and/or PDGFβ-positive CH; 35 patients (70%) had stable disease with a 64% clinical benefit rate (i.e., partial/complete response or stable disease) and a median progression-free survival of 9 months [80]. The gene discussed is PDGFB; the disease is cyclic hematopoiesis.